Ex vivo drug testing in patient-derived papillary renal cancer cells reveals EGFR and the BCL2 family as therapeutic targets

dc.contributor.authorAngori, Silvia
dc.contributor.authorBanaei-Esfahani, Amir
dc.contributor.authorMühlbauer, Katharina
dc.contributor.authorBolck, Hella A.
dc.contributor.authorKahraman, Abdullah
dc.contributor.authorKarakulak, Tülay
dc.contributor.authorPoyet, Cédric
dc.contributor.authorFeodoroff, Michaela
dc.contributor.authorPotdar, Swapnil
dc.contributor.authorKallioniemi, Olli
dc.contributor.authorPietiäinen, Vilja
dc.contributor.authorSchraml, Peter
dc.contributor.authorMoch, Holger
dc.date.accessioned2023-10-11T07:59:21Z
dc.date.available2023-10-11T07:59:21Z
dc.date.issued2023
dc.identifier.doi10.1016/j.euf.2023.03.005
dc.identifier.issn2405-4569
dc.identifier.urihttps://irf.fhnw.ch/handle/11654/38092
dc.identifier.urihttps://doi.org/10.26041/fhnw-5444
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofEuropean Urology Focus
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc500 - Naturwissenschaften und Mathematik
dc.titleEx vivo drug testing in patient-derived papillary renal cancer cells reveals EGFR and the BCL2 family as therapeutic targets
dc.type01A - Beitrag in wissenschaftlicher Zeitschrift
dspace.entity.typePublication
fhnw.InventedHereYes
fhnw.ReviewTypeAnonymous ex ante peer review of a complete publication
fhnw.affiliation.hochschuleHochschule für Life Sciencesde_CH
fhnw.affiliation.institutInstitut für Chemie und Bioanalytikde_CH
fhnw.openAccessCategoryHybrid
fhnw.publicationStatePublished
relation.isAuthorOfPublicationa6b12c58-f330-4302-9e09-78e47baf80d6
relation.isAuthorOfPublication.latestForDiscoverya6b12c58-f330-4302-9e09-78e47baf80d6
Dateien
Originalbündel
Gerade angezeigt 1 - 1 von 1
Lade...
Vorschaubild
Name:
1-s2.0-S2405456923000676-main.pdf
Größe:
1.84 MB
Format:
Adobe Portable Document Format
Beschreibung:
Lizenzbündel
Gerade angezeigt 1 - 1 von 1
Lade...
Vorschaubild
Name:
license.txt
Größe:
1.36 KB
Format:
Item-specific license agreed upon to submission
Beschreibung: